ArticleJournal of hand surgery global online2026
Is Parkinson Disease a Risk Factor After Total Elbow Arthroplasty? Midterm Survivorship in a Matched Cohort.
Article in Journal of hand surgery global online, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Parkinson disease (PD) has been associated with elevated rates of periprosthetic fracture, periprosthetic joint infection, and reduced implant survivorship following total hip and knee arthroplasty; however, it remains unclear whether these risks extend to total elbow arthroplasty (TEA). The purpose of this study was to evaluate whether PD is associated with worse midterm survivorship and higher complication risk after TEA compared with matched controls. Methods: A retrospective, matched cohort study was performed using the PearlDiver administrative claims database. Adult patients undergoing primary TEA were identified, and PD was defined by diagnostic claims recorded on or before the index procedure. Patients with PD were matched 1:4 to non-PD controls by age and sex. Primary end points were aseptic loosening, periprosthetic joint infection, and periprosthetic fracture. Secondary outcomes included revision TEA, operative fixation of periprosthetic fracture, and a composite adverse outcome defined as the first occurrence of any complication or reoperation. Patients were followed until first event, end of enrollment, or 5 years. Kaplan-Meier analysis was used to estimate event-free survivorship, with log-rank testing and Cox proportional hazards regression used for comparison. Results: After matching, 675 patients were included: 135 with PD and 540 controls. Overall adverse events were uncommon, and survivorship remained high across all end points. There was no significant difference in 5-year composite adverse event-free survivorship between PD and controls (84.4% [95% CI: 77.9-91.4] vs 83.4% [95% CI: 79.9-87.0]; log-rank Conclusions: Parkinson disease was not associated with worse 5-year survivorship or higher risk of implant-threatening complications after TEA. These findings suggest that PD diagnosis alone may not confer increased midterm risk following TEA. Type of study/level of evidence: Prognostic III, retrospective matched cohort study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.